Skip to main content

Table 1 Clinico-pathological data

From: Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer

  Biobank 1 Biobank 2
Clinical features Control patients (N) Invasive cancer (C) Control patients (N) Invasive cancer (C)
Gender
 Female 12 (57%) 9 (47%) 24 (52%) 16 (59%)
 Male 9 (43%) 10 (53%) 22 (48%) 11 (41%)
Age (years, Median [range]) 52 [19–64] 69 [51–87] 52 [23–81] 66 [27–90]
Weight (kg, Median [range]) 70 [48–115] 70 [50–100] 71 [42–130] 65 [40–89]
Size (cm, Median [range]) 164 [155–193] 168 [157–182] 168 [145–187] 165 [153–185]
Cancer stage
 I   2 (11%)   4 (15%)
 II   5 (26%)   10 (37%)
 III   5 (26%)   7 (26%)
 IV   7 (37%)   6 (22%)
Tumor location
 Right colon   11 (60%)   N/A
 Left colon   8 (40%)   N/A
  1. Patients were selected randomly from two collections and included for the validation of FXIII by ELISA and AP-F13A1 by PRM assays. For cancer patients, they were classified according to cancer’s stage (I, II, III, IV) and the location of the primary tumor